Liminatus Pharma, Inc. SEC filings LIMNW
Liminatus Pharma, Inc. has 109 filings in SEC EDGAR's recent list, going back to May 2, 2023. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G | Ownership over 5% (passive) | Jul 22, 2026 | — |
| 4 | Insider transaction | Jul 14, 2026 | Jul 2, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 14, 2026 | — |
| 4 | Insider transaction | Jul 6, 2026 | Jun 24, 2026 |
| 3 | Initial insider ownership | Jul 6, 2026 | Jun 24, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jul 6, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 20, 2026 | — |
| 3 | Initial insider ownership | Aug 15, 2025 | Apr 30, 2025 |
| 3 | Initial insider ownership | Jul 23, 2025 | Jul 10, 2025 |
| 3 | Initial insider ownership | Jul 21, 2025 | Jul 10, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 27, 2025 | — |
| 3 | Initial insider ownership | Jun 27, 2025 | Apr 30, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 26, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 26, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 26, 2025 | — |
| 3 | Initial insider ownership | Jun 16, 2025 | Apr 30, 2025 |
| SCHEDULE 13D | Ownership over 5% (active) | May 8, 2025 | — |
| SCHEDULE 13D | Ownership over 5% (active) | May 7, 2025 | — |
| 3 | Initial insider ownership | May 1, 2025 | Apr 30, 2025 |
| 3 | Initial insider ownership | Apr 30, 2025 | Apr 30, 2025 |
| 3 | Initial insider ownership | Apr 30, 2025 | Apr 30, 2025 |
| 3 | Initial insider ownership | Apr 30, 2025 | Apr 30, 2025 |
| 3 | Initial insider ownership | Apr 30, 2025 | Apr 30, 2025 |
| 3 | Initial insider ownership | Apr 30, 2025 | Apr 30, 2025 |
| 3 | Initial insider ownership | Apr 30, 2025 | Apr 30, 2025 |
| 3 | Initial insider ownership | Apr 30, 2025 | Apr 30, 2025 |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LIMN (Nasdaq), LIMNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cerritos, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1971387
- Former names
- Iris Parent Holding Corp. (until Feb 7, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.